At the IGTP TODAY
The 2024 call for Knowledge Industry grants by AGAUR has awarded €528,000 to seven projects from IGTP. The grants will enhance the valorisation and transfer of these innovative projects.
IGTP has received grants for six research projects in two calls from the Spanish Research Agency, under the State Plan for Scientific and Technical Research and Innovation 2021-2023.
Debios Diagnostics aims to improve diagnostics for diseases of the urinary and reproductive systems through non-invasive testing, while HealthTech Innovations S.L. seeks to enhance operating room efficiency and safety by integrating advanced technology that supports nursing staff and optimises sterilisation processes.
The Spanish Ministry of Science, Innovation and Universities (MICIU) has awarded €1.7 million, and the European Commission an additional €466,000, to support the development of a gene therapy for Friedreich's ataxia by Biointaxis, a spin-off from IGTP.
The European Commission has granted €2,999,101 in funding to the NanoBiCar project, coordinated by Universitat Politècnica de València, with the participation of the Germans Trias i Pujol Research Institute (IGTP). The grant falls within the EIC Pathfinder Program of the European Innovation Council (EIC), a highly competitive program aimed at identifying, developing, and scaling up breakthrough technologies and disruptive innovations.
_1728469313.jpg)
DevsHealth, a leading company in artificial intelligence (AI) driven drug discovery, and the Germans Trias i Pujol Research Institute (IGTP), a public research centre in biomedical sciences, have announced a new partnership to develop new antibiotics for multi-resistant Staphylococcus aureus infections.
The Innomed Awards, held at the Can Ruti Campus, celebrated significant advancements in biomedical innovation and reinforced the commitment to collaboration among the leading healthcare and research institutions of this health ecosystem and its surroundings.
IGTP presented yesterday, 10 June, the initiative with a total of 45 companies and entities participating, which will promote the research and development of these medicines to generate an economic and social impact in Catalonia.
CMCiB-IGTP has renewed its certificate of compliance with Good Laboratory Practices (GLP) in accordance with Directive 2004/9/EC.
Researchers from IGTP and Ahead Therapeutics have been exploring a treatment based on liposome-type nanoparticles to address the autoimmunity of type 1 diabetes for years. A study recently published in the Journal of Autoimmunity examines the response of macrophages to this immunotherapy, serving as a preliminary step before clinical trials.
